← Eichor
Condition: Locally Advanced Triple Negative Breast Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Triple Negative Breast Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Nega
Phase 2 · 2 location(s) · Fudan University · NCT06636981Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Phase 2 · 1 location(s) · QIAO LI · NCT06955156Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Phase 2 · 5 location(s) · European Institute of Oncology · NCT06690840Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05806060A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06371274Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Phase N/A · 1 location(s) · Fudan University · NCT07705438A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07208149A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Trip
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06471205A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Phase 1 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT04360941First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2 · 1 location(s) · Fudan University · NCT05582499FMD and Neoadjuvant Chemo-immunotherapy in TNBC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07378306Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06434064A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecul
Phase 1/Phase 2 · 8 location(s) · Marengo Therapeutics, Inc. · NCT06827613I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2 · 42 location(s) · QuantumLeap Healthcare Collaborative · NCT01042379Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
EARLY_Phase 1 · 1 location(s) · Rima Patel · NCT06637306A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1 · 2 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT05746897177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06492005A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recu
Phase 2/Phase 3 · 295 location(s) · Bristol-Myers Squibb · NCT06926868Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Andr
Phase 3 · 1 location(s) · Fudan University · NCT05954442
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.